Teriparatide Therapy and Beta-Tricalcium Phosphate Enhance Scaffold Reconstruction of Mouse Femoral Defects
- 1 February 2011
- journal article
- research article
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 17 (3-4) , 389-398
Abstract
To investigate the efficacy of endocrine parathyroid hormone treatment on tissue-engineered bone regeneration, massive femoral defects in C57Bl/6 mice were reconstructed with either 100:0 or 85:15 poly-lactic acid (PLA)/beta-tricalcium phosphate (β-TCP) scaffolds (hereafter PLA or PLA/βTCP, respectively), which were fabricated with low porosity (<30%) to improve their structural rigidity. Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline. Bone regeneration was assessed longitudinally using planar X-ray and quantitative microcomputed tomography, and the reconstructed femurs were evaluated at 9 weeks either histologically or biomechanically to determine their torsional strength and rigidity. Teriparatide treatment increased bone volume and bone mineral content significantly at 6 weeks and led to enhanced trabeculated bone callus formation that appeared to surround and integrate with the scaffold, thereby establishing union by bridging bone regeneration across the segmental defect in 30% of the reconstructed femurs, regardless of the scaffold type. However, the bone volume and mineral content in the PLA reconstructed femurs treated with teriparatide was reduced at 9 weeks to control levels, but remained significantly increased in the PLA/βTCP scaffolds. Further, bridged teriparatide-treated femurs demonstrated a prototypical brittle bone torsion behavior, and were significantly stronger and stiffer than control specimens or treated specimens that failed to form bridging bone union. Taken together, these observations suggest that intermittent, systemic parathyroid hormone treatment can enhance bone regeneration in scaffold-reconstructed femoral defects, which can be further enhanced by mineralized (βTCP) particles within the scaffold.Keywords
This publication has 48 references indexed in Scilit:
- Evaluation of dense polylactic acid/beta‐tricalcium phosphate scaffolds for bone tissue engineeringJournal of Biomedical Materials Research Part A, 2010
- Beta-tricalcium phosphate exerts osteoconductivity through α2β1 integrin and down-stream MAPK/ERK signaling pathwayBiochemical and Biophysical Research Communications, 2010
- Nmp4/CIZ: Road block at the intersection of PTH and loadBone, 2010
- Teriparatide (1‐34 human PTH) regulation of osterix during fracture repairJournal of Cellular Biochemistry, 2008
- Safety Assessment of Intradiscal Gene Therapy IISpine, 2008
- Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiationBone, 2008
- Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusionInternational Orthopaedics, 2007
- Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1–34) on chondrogenesis in a model of experimental fracture healingBone, 2005
- Safety of Adeno-Associated Virus as Cochlear Gene Transfer Vector: Analysis of Distant Spread Beyond Injected CochleaeMolecular Therapy, 2000
- PTH: A future role in the management of osteoporosis?Journal of Bone and Mineral Research, 1996